NBIX
NASDAQ
$173
Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Sector:
Healthcare
Buy
Target: $200.24 (+15.75%)
Market Cap
$17B
PEG Ratio
0.21
Revenue 5Y CAGR
+24.30%
FCF 5Y CAGR
+25.83%
Price Chart
Valuation
Market Cap$17B
P/E25.72
Forward P/E24.10
PEG0.21
P/S5.74
P/B5.23
Profitability
Total Revenue (TTM)$3.10B
Gross Profit (TTM)$2B
EBITDA$816M
Profit Margin24.3%
Operating Margin23.7%
EPS$6.69
Financial Health
Free Cash Flow Yield4.78%
Growth & Risk
EPS 5Y CAGR+9.25%
Revenue 5Y CAGR+24.30%
FCF 5Y CAGR+25.83%
Beta (5Y)0.79
Sharpe Ratio0.85